Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2020 · 10-Q
Revenue$87.10M$87.10M+188.1% vs Q1 2019 Net Income-$40.26M-$40.26MN/M vs Q1 2019 EPS Diluted-$0.59-$0.59N/M vs Q1 2019 Operating Income-$43,192,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$109,813,000N/M Margins · derivedOperating margin-49.6%+272.9 pt vs Q1 2019
Net margin-46.2%+261.7 pt vs Q1 2019
ended Mar 31, 2020 · filed Apr 30, 2020 · 30 d after period end